Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, Grieco FA, Del Guerra S, DAleo V, Piro S, Marselli L, Boggi U, Filipponi F, Tinti L, Salvini L, Wollheim CB, Purrello F, Dotta F
[DOI] [PMC free article] [PubMed] [Google Scholar] 78.Schlgl H., Kabisch S., Horstmann A., Lohmann G., Mller K., Lepsien J., Busse-Voigt F., Kratzsch J., Pleger B., Villringer A., et al
Novo Nordisk fights back with oral GLP-1 data in obesity Shortly after reporting weaker-than-expected sales of its injectable GLP-1 drugs, Novo Nordisk revealed clinical results with an oral alternative that suggest it can offer comparable efficacy with convenient, daily dosing
While various GLP-1 RAs such as Semaglutide (Wegovy, Ozempic), Dulaglutide (Trulicity), Lixisenatide (Adlyxin), and Tirzepatide (Mounjaro, Zepbound) are commonly prescribed, their specific pharmacokinetics and effects on gastric motility vary, adding complexity to perioperative care (Almandoz et al
91 , L6062 (2006)
